干旱区生态环境知识资源中心(Arid): Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies

Arid

DOI	10.18502/jovr.v16i1.8250
	Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies
	Joondeph, Brian C.; Willems, Paul; Raber, Thomas; Duchateau, Luc; Markoff, Joseph
通讯作者	Joondeph, BC (corresponding author), 8101 E Lowry Blvd,Suite 210, Denver, CO 80230 USA.
来源期刊	JOURNAL OF OPHTHALMIC & VISION RESEARCH
ISSN	2008-2010
EISSN	2008-322X
出版年	2021
卷号	16 期号:1 页码:42-55
英文摘要	Purpose: To assess the effect of patient baseline characteristics on the efficacy of ocriplasmin treatment for symptomatic vitreomacular adhesion (VMA) with full-thickness macular hole (FTMH) from phase 3/4 studies. Methods: Patients with symptomatic VMA and FTMH at baseline and receiving ocriplasmin treatment 125..g were pooled from the MIVI-TRUST, OASIS, and ORBIT studies. Multivariable logistic regression analysis was used to evaluate whether patient baseline characteristics were predictors of having VMA resolution by Day 28 and FTMH closure by Month 6. Results: Two hundred and seventy-four patients receiving ocriplasmin treatment were assessed. Overall, 22.6% (62/274) of the patients experienced both VMA resolution by Day 28 and non-surgical FTMH closure by Month 6. Patients with FTMH <= 250 mu m at baseline had a significantly higher success rate compared to those with FTMH >400 mu m (29.9% [41/137] vs 2.2% [1/48]; P = 0.009). In patients with VMA resolution by Day 28, both small FTMH size (P = 0.001) and FTMH width at RPE (P = 0.012) were significantly associated with a higher FTMH closure rate. Patients with VMA resolution had higher rates of FTMH closure. Previously identified baseline predictive factors, including age, lens status, or presence of epiretinal membrane (ERM) were not found to be predictive of both VMA release and FTMH closure. Conclusion: The analysis revealed that FMTH <= 250 mu m was the only factor predictive for achieving both pharmacological VMA resolution by Day 28 and nonsurgical FTMH closure by Month 6; neither lens status or presence of ERM, previously identified baseline characteristics favoring VMA resolution, showed statistically significant predictive power for both outcomes.
英文关键词	Ocriplasmin Full-thickness Macular Hole Vitreomacular Adhesion Symptomatic Vitreomacular Adhesion Vitreomacular Traction Vitreoretinal Interface
类型	Article
语种	英语
开放获取类型	Green Published, gold
收录类别	ESCI
WOS记录号	WOS:000665056800007
WOS关键词	NUCLEAR SCLEROTIC CATARACT ; INTRAVITREAL OCRIPLASMIN ; TRACTION RELEASE ; NATURAL-HISTORY ; VISUAL OUTCOMES ; CLINICAL-COURSE ; VITRECTOMY ; STAGE-2 ; PROGRESSION ; PREDICTORS
WOS类目	Ophthalmology
WOS研究方向	Ophthalmology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/352895
作者单位	[Joondeph, Brian C.] Colorado Retina Associates, Denver, CO USA; [Willems, Paul; Raber, Thomas] Oxurion, Leuven, Belgium; [Duchateau, Luc] Univ Ghent, Biometr Res Grp, Ghent, Belgium; [Markoff, Joseph] Wills Eye Hosp & Res Inst, Philadelphia, PA USA; [Markoff, Joseph] Thomas Jefferson Med Coll, Philadelphia, PA USA
推荐引用方式 GB/T 7714	Joondeph, Brian C.,Willems, Paul,Raber, Thomas,et al. Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies[J],2021,16(1):42-55.
APA	Joondeph, Brian C.,Willems, Paul,Raber, Thomas,Duchateau, Luc,&Markoff, Joseph.(2021).Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies.JOURNAL OF OPHTHALMIC & VISION RESEARCH,16(1),42-55.
MLA	Joondeph, Brian C.,et al."Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies".JOURNAL OF OPHTHALMIC & VISION RESEARCH 16.1(2021):42-55.